The growing field of liquid biopsy and its Snowball effect on reshaping cancer management

The Journal of Liquid Biopsy, Journal Year: 2025, Volume and Issue: unknown, P. 100293 - 100293

Published: March 1, 2025

Liquid biopsy (LB) has emerged as a transformative tool in oncology, providing minimally invasive approach for tumor detection, molecular characterization, and real-time treatment monitoring. By analyzing circulating DNA (ctDNA), cells (CTCs), extracellular vesicles (EVs), microRNA (miRNA), LB enables comprehensive profiling without the need traditional tissue biopsies. Over past decade, research this field expanded exponentially, leading to integration of into clinical practice specific cancer types, including lung breast cancer. In 2024, Journal Biopsy (JLB) published innovative studies exploring latest advancements technologies, biomarkers, their applications minimal residual disease (MRD) monitoring, therapy response assessment. This review synthesizes recent findings on role monitoring across different with particular focus newly context within translational research. Additionally, it highlights emerging techniques such fragmentomics, artificial intelligence, multiomics, paving way more precise, personalized decisions. Despite these advancements, challenges remain standardizing methodologies, optimizing validation, integrating routine oncological workflows. mini-review evolving landscape its potential revolutionize diagnosis, therapeutic decision-making, ushering new era precision oncology.

Language: Английский

---

Liquid Biopsies in the Early Diagnosis, Prognosis, and Tailored Treatment of Colorectal Cancer

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 927 - 927

Published: March 8, 2025

Introduction: Liquid biopsies provide a less-invasive option to tissue for the early diagnosis, prognosis, and tailored therapy of colorectal cancer (CRC). CRC is major cause cancer-related death, identification essential improving patient outcomes. Review: Conventional diagnostic techniques, including colonoscopy biopsy, may be enhanced by liquid that examine circulating tumor cells (CTCs), DNA (ctDNA), extracellular vesicles (EVs), other indicators present in body fluids. These markers significant insights into biology, heterogeneity, therapeutic response. CTCs detected early-stage have prognostic significance disease recurrence survival, while ctDNA investigation uncover genetic mutations, epigenetic alterations, development. The minimal residual (MRD) postsurgery correlates with an elevated risk unfavorable underscoring its use assessing treatment effectiveness. Furthermore, non-coding RNAs (ncRNAs) contained inside EVs potential prospective biomarkers targets, facilitating diagnosis assessment. Notwithstanding biopsies, obstacles persist assay standardization, sensitivity enhancement, management heterogeneity. Additional extensive research required determine their function clinical practice. Conclusion: Overall, serve as instrument real-time monitoring, evaluating responses, directing individualized strategies patients.

Language: Английский

---

Translating the multifaceted use of liquid biopsy to management of early disease in pancreatic adenocarcinoma

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: March 13, 2025

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality, primarily due to late stage at diagnosis. This review examines the multifaceted applications liquid biopsy and circulating tumor DNA (ctDNA) analysis in diagnosis management PDAC. We current literature on technological advancements such as next generation sequencing (NGS) digital droplet PCR (ddPCR) well multi-omics technologies, highlighting their potential for accurate molecular subtyping through ctDNA analysis. highlights significant role assessment behavior, disease subtyping, prediction monitoring treatment response, evaluation minimal residual disease. discuss implications integrating techniques into clinical practice its challenges limitations. By drawing insights from recent studies, this aims provide comprehensive overview how can enhance early strategies underscore need additional prospective studies trials validate feasibility accuracy order establish utility, with ultimate goal routine incorporation improve patient outcomes transform landscape

Language: Английский

---

Study on the clinical application value of a new type of magnetic nanomicrospheres that can be used for circulating tumor cell sorting in lung cancer

Materials Today Chemistry, Journal Year: 2025, Volume and Issue: 45, P. 102679 - 102679

Published: April 1, 2025

Language: Английский

---